SCIg for Inborn Immunity: Effective Immunoglobulin Therapy
- Patients with inborn errors of immunity (IEI) who received immunoglobulin replacement therapy (IRT) via conventional subcutaneous immunoglobulin (cSCIg) experienced fewer viral infections compared to those receiving intravenous immunoglobulin...
- IEIs, though often rare, are monogenic immune system disorders that can lead to immunodeficiency, autoinflammation, allergy, or cancer.While managing IEIs is challenging,immunoglobulin replacement therapy (IRT) has become standard...
- The most common immunoglobulin routes are IVIG and SCIg, each with benefits and drawbacks.
Discover how conventional SCIg reduces viral infections in people with inborn errors of immunity (IEI), a key finding for enhancing immunoglobulin replacement therapy. According to a recent study, patients using this approach experienced fewer viral infections compared to those on IVIG or facilitated SCIg. The research, published in the *European Journal of Pediatrics*, compared different routes of immunoglobulin replacement therapy and uncovered that conventional SCIg correlated with a important drop in patient infections. The team at News Directory 3 is always looking for pivotal data that improves reader’s health. The most common infections included adenovirus, influenza A, and human rhinovirus/enterovirus. Learn how these findings impact the future of viral infection protection; discover what’s next for the future of immunoglobulin treatments.
Conventional SCIg Reduces Viral Infections in Immunocompromised Patients
Updated June 07, 2025
Patients with inborn errors of immunity (IEI) who received immunoglobulin replacement therapy (IRT) via conventional subcutaneous immunoglobulin (cSCIg) experienced fewer viral infections compared to those receiving intravenous immunoglobulin (IVIG) or facilitated SCIg (fSCIg). These are the findings of a study published in the European Journal of Pediatrics.
IEIs, though often rare, are monogenic immune system disorders that can lead to immunodeficiency, autoinflammation, allergy, or cancer.While managing IEIs is challenging,immunoglobulin replacement therapy (IRT) has become standard for antibody production deficiencies. The study highlights the importance of comparing different IRT routes to understand their impact on viral infection incidence and improve immunoglobulin replacement therapy outcomes.
The most common immunoglobulin routes are IVIG and SCIg, each with benefits and drawbacks. IVIG allows for higher immunoglobulin G (igg) doses, crucial because IgG concentration is inversely related to infection risk. Though, IVIG can disrupt quality of life, and IV access can be tough. SCIg, administered at home, carries less risk of adverse events but delivers less treatment than IVIG. Differences also exist within SCIg routes; fSCIg delivers large IgG volumes with fewer needle insertions, while cSCIg involves weekly subcutaneous injections to maintain IgG levels. Therefore, evaluating the safety and efficacy of various immunoglobulin management routes is crucial.
The study compared viral infection rates in 58 immunocompromised IEI patients receiving IRT via different routes between January and March 2023. Patients were divided into IVIG, cSCIg, and fSCIg groups, and their symptoms and infection rates were assessed. The most common route was IVIG (55.1%), followed by cSCIg (27.5%). IVIG treatments were hospital-administered,while cSCIg and fSCIg were administered at home. Researchers calculated viral infection rates by analyzing PCR results for each infection over three months,finding an overall infection frequency of 3.79%.
The IVIG route had a 4.2% infection rate, SCIg 2.5%, and fSCIg 4.4%. The fewest viral infections occurred in patients treated with cSCIg (P < .05). Infections in fSCIg or IVIG patients were typically detected in the third and fourth weeks. Adenovirus (21.8%), influenza A (16.4%), and human rhinovirus/enterovirus (16.4%) were the most observed infections. These findings suggest that conventional SCIg may offer the most benefit for immunocompromised patients, with a 50% reduction in viral infections compared to other routes, while maintaining serum IgG levels.
“This study suggests that cSCIg treatment is a more effective treatment option for immunocompromised patients prone to viral infection,” the investigators wrote. “Still, it is indeed also a safe method to administer due to the optimum IgG threshold level and quality of life score it provides.”
What’s next
Health care providers should monitor IgG levels during IRT and manage any adverse events. further research could explore the long-term benefits and optimal use of cSCIg in managing IEIs and reducing viral infection risks.